Dowling & Yahnke’s Moderna MRNA Stock Holding History

Dowling & Yahnke’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-904	Closed	-$230K	–	385
2021 Q4	$230K	Sell	904 -50	-5%	-$14.6K	0.01%	355
2021 Q3	$367K	Hold	954	–	–	0.02%	291
2021 Q2	$224K	Buy	+954	New	+$170K	0.01%	336

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dowling & Yahnke's MRNA Position: Q1 2022 in Review

Dowling & Yahnke sold out of Moderna (MRNA) in Q1 2022, closing a stake of 904 shares — an estimated $230K sold.

Dowling & Yahnke first reported a position in MRNA in Q2 2021 and held it in 3 quarters. The position peaked at $367K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Dowling & Yahnke reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Dowling & Yahnke sold 904 Moderna shares in Q1 2022, an estimated $230K.
Dowling & Yahnke first reported a position in Moderna in Q2 2021 and held it in 3 quarters.
Dowling & Yahnke's Moderna position peaked at $367K in Q3 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Dowling & Yahnke's 13F filing for Q1 2022, filed 4 May 2022.